Evidence map›Paper›PMID 41042819›Full record

ArticlePLoS computational biology2025

RNAtranslator: Modeling protein-conditional RNA design as sequence-to-sequence natural language translation.

Sobhan Shukueian Tabrizi, Sina Barazandeh, Helyasadat Hashemi Aghdam, A Ercument Cicek

Abstract read
In one paragraph

Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sobhan Shukueian TabriziDepartment of Computer Engineering, Bilkent University, Ankara, Türkiye.
Sina BarazandehComputational Biology Department, Carnegie Mellon University, Pittsburgh, Pennsylvania, United States of America.
Helyasadat Hashemi AghdamDepartment of Computer Engineering, Bilkent University, Ankara, Türkiye.
A Ercument CicekDepartment of Computer Engineering, Bilkent University, Ankara, Türkiye.ORCID 0000-0001-8613-6619

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein-RNA interactions are essential in gene regulation, splicing, RNA stability, and translation, making RNA a promising therapeutic agent for targeting proteins, including those considered undruggable. However, designing RNA sequences that selectively bind to proteins remains a significant challenge due to the vast sequence space and limitations of current experimental and computational methods. Traditional approaches rely on in vitro selection techniques or computational models that require post-generation optimization, restricting their applicability to well-characterized proteins. We introduce RNAtranslator, a generative language model that formulates protein-conditional RNA design as a sequence-to-sequence natural language translation problem for the first time. By learning a joint representation of RNA and protein interactions from large-scale datasets, RNAtranslator directly generates binding RNA sequences for any given protein target without the need for additional optimization. Our results demonstrate that RNAtranslator produces RNA sequences with natural-like properties, high novelty, and enhanced binding affinity compared to existing methods. This approach enables efficient RNA design for a wide range of proteins and even proteins with no RNA-interaction data available, paving the way for new RNA-based therapeutics and synthetic biology applications.

Indexed as

RNARNA-Binding ProteinsBase SequenceComputational BiologyHumansProtein BindingProtein BiosynthesisRNARNA-Binding Proteins

Identifiers

PMID41042819
PMCPMC12510665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.